Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-2298
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-28T18:34:44.438218Z
status: published
lens: trace
sector: health
headline: Artificial intelligence–based tumor detection using stimulated Raman histology in patients undergoing neurosurgical biopsies
dek: OBJECTIVE Intraoperative confirmation of diagnostic tumor tissue is critical in neurosurgical biopsies, particularly in stereotactic procedures, in which sampling error remains a major limitation. Stimulated Raman histology (SRH) enables rapid, label-free tissue imaging directly in the operating room. This study aimed to evaluate the performance of intraoperative SRH combined with artificial intelligence (AI)–based tumor detection using a CE (Conformité Européenne)–certified algorithm under routine clinical cond…
gain_title: In 204 scans from 89 biopsy patients, the Glioma Reveal algorithm detected tumor tissue with 80.9% initial accuracy, rising to 94.1% after expert review, giving rapid intraoperative confirmation of tumor tissue.
problem_title: The algorithm reached only 62.5% accuracy on nonneoplastic lesions because of reactive mimics, and sensitivity for gliomas and lymphomas was 78.8%, with false negatives driven by tissue heterogeneity.
trace_subject: AI tumor detection on stimulated Raman histology scans during neurosurgical biopsies
gain_reading: In 204 scans from 89 biopsy patients, the Glioma Reveal algorithm detected tumor tissue with 80.9% initial accuracy, rising to 94.1% after expert review, giving rapid intraoperative confirmation of tumor tissue.
gain_evidence: Analysis of 204 SRH scans obtained in 89 patients using the Glioma Reveal algorithm showed an initial overall accuracy of 80.9% for tumor tissue detection | After expert review of the misclassified cases, accuracy increased to 94.1%
problem_reading: The algorithm reached only 62.5% accuracy on nonneoplastic lesions because of reactive mimics, and sensitivity for gliomas and lymphomas was 78.8%, with false negatives driven by tissue heterogeneity.
problem_evidence: initial accuracy remained at 62.5% regardless of expert review due to reactive mimics
quick_read: Researchers retrospectively reviewed consecutive neurosurgical biopsy patients at a single center who had intraoperative stimulated Raman histology imaging between December 2020 and October 2025. A CE-certified algorithm, Glioma Reveal, scored each scan for tumor cells, and results were compared against routine histopathology.

The work matters because sampling error is a major limitation in biopsies, especially stereotactic ones, and fast confirmation of representative tissue could help. Still, the strongest accuracy figures depended on neuropathologist review of discordant cases, and the tool performed poorly on nonneoplastic lesions, so its standalone reliability remains uncertain.
limitation: This was a retrospective single-center study, and the higher accuracy figures relied on expert re-review of discordant cases rather than the algorithm alone; heterogeneity and sampling differences affected metrics.
tag: Dual reading
key_points: The study covered 204 scans from 89 patients, analyzed at the scan level for specific regions of interest. | Initial overall accuracy was 80.9%, increasing to 94.1% after a neuropathologist reviewed misclassified cases. | For gliomas and lymphomas (70 patients, 168 scans), sensitivity was 78.8% and specificity 100.0%. | Expert review found 80.6% (25 scans) of false negatives were morphologically correct within the specific region despite whole-specimen positivity. | Accuracy for nonneoplastic lesions stayed at 62.5% because of reactive mimics.
rundown: Patients were included if they had neurosurgical biopsy with intraoperative stimulated Raman histology, a rapid, label-free imaging method used in the operating room. Each tissue sample then received routine histopathological analysis, which served as the reference.

Cases were grouped into common tumor entities, rare tumor entities and nonneoplastic lesions. Within gliomas and lymphomas, initial accuracy was 81.5% and rose to 96.4% after correcting for false negatives that the expert judged morphologically correct.

In rare tumors (8 patients, 20 scans), accuracy rose from 90.0% to 100.0% after expert review. The authors conclude that performance is robust but that intraspecimen heterogeneity and spatial sampling differences significantly affect diagnostic metrics.
sources:
- peer_reviewed | Neurosurgical Focus | https://doi.org/10.3171/2026.8.focus26457 | 2026-10-28
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

cfb0cbd9d75a7f090f10ab104c853257a7c82aeccbc6dbe7befea6f57fb6d2e4

previous

0000000000000000000000000000000000000000000000000000000000000000